Semaglutide: Mechanism, Research & UK Safety Profile
Also known as: Ozempic, Wegovy, Rybelsus, NNC0113-0217
A long-acting GLP-1 receptor monoagonist developed by Novo Nordisk, widely researched in STEP and SUSTAIN trials and MHRA-licensed in the UK for type 2 diabetes and chronic weight management.
Molecular formula
C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight
4113.6 Da
Half-life
Approximately 7 days (168 hours) for subcutaneous semaglutide, achieved through C-18 fatty diacid–mediated albumin binding that dramatically reduces renal clearance and DPP-4-mediated proteolysis. Oral semaglutide has a similar terminal half-life but lower and more variable bioavailability.
Category
GLP-1/GIP Agonists
Overview
Semaglutide is a synthetic 31-amino acid glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk A/S. It is structurally based on native human GLP-1 with three key modifications: substitution of alanine with aminoisobutyric acid at position 8 (conferring DPP-4 resistance), attachment of a C-18 fatty diacid chain via a linker at lysine 34 (enabling albumin binding and extending half-life), and replacement of arginine with lysine at position 34. These combined modifications produce a half-life of approximately one week, allowing once-weekly subcutaneous dosing.
In the United Kingdom, semaglutide is an MHRA-licensed prescription medicine available in three formulations: Ozempic (0.5 mg, 1 mg, and 2 mg subcutaneous injection) licensed for the management of type 2 diabetes; Wegovy (2.4 mg subcutaneous injection) licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities; and Rybelsus (3 mg, 7 mg, and 14 mg oral tablet) licensed for type 2 diabetes. All formulations are prescription-only medicines and may only be supplied through legitimate prescribing pathways.
The clinical evidence base for semaglutide is among the most extensive of any metabolic peptide. The SUSTAIN programme (SUSTAIN 1–7 and SUSTAIN-FORTE) established its glycaemic efficacy in type 2 diabetes; the STEP programme (STEP 1–8) characterised weight-management efficacy; and the SELECT cardiovascular outcomes trial—published in The New England Journal of Medicine in 2023—demonstrated a 20% relative reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes, the first pharmacological weight-management agent to demonstrate such a benefit in a pre-specified primary outcome.
Mean weight reductions of approximately 14.9% at 68 weeks in STEP 1 (the primary weight-management trial) established semaglutide 2.4 mg as the benchmark against which subsequent agents—including tirzepatide and retatrutide—are compared. For researchers studying incretin biology, semaglutide serves as the pharmacological reference standard for GLP-1 receptor agonism, with a uniquely deep and well-characterised clinical dataset spanning cardiovascular, hepatic, renal, and neurological outcome domains.
Discovery & Research History
Semaglutide was developed by Novo Nordisk as the successor to liraglutide, building on structural insights gained from the company's earlier GLP-1 receptor agonist programme that had culminated in liraglutide's approval in 2010. The scientific challenge was extending the half-life of the GLP-1 analogue from liraglutide's approximately 13 hours—sufficient for once-daily dosing—to a full week, enabling once-weekly subcutaneous administration.
The half-life extension strategy combined two innovations: first, enhanced resistance to dipeptidyl peptidase-4 (DPP-4), the protease responsible for native GLP-1's rapid cleavage in plasma, achieved by the position-8 aminoisobutyric acid substitution; and second, high-affinity, non-covalent albumin binding via a C-18 fatty diacid chain attached to the peptide through a short hydrophilic spacer. Albumin-bound peptide is protected from renal clearance and proteolytic degradation, and its large hydrodynamic radius slows glomerular filtration. Novo Nordisk's medicinal chemistry team, led by researchers including Morten Bagger and colleagues, completed the structural optimisation of NNC0113-0217 in the early 2010s.
Phase 3 clinical evaluation began with the SUSTAIN programme, with SUSTAIN-1 through SUSTAIN-7 collectively establishing superiority over multiple comparators in type 2 diabetes management. SUSTAIN-6, the cardiovascular outcomes trial, demonstrated non-inferiority for MACE alongside a significant reduction in non-fatal stroke, supporting the first CV claims for a GLP-1 receptor agonist in the European labelling.
The STEP programme followed, investigating the much higher 2.4 mg dose for weight management in populations without mandatory diabetes—an indication that Novo Nordisk pursued after observing the dramatic weight-loss effects in SUSTAIN participants. STEP 1 results published in The New England Journal of Medicine in 2021 established weight management as a primary indication. The subsequent SELECT trial, enrolling 17,604 participants and running for over four years, represented the definitive cardiovascular outcomes study, with results published in 2023 establishing semaglutide as the first pharmacological weight-management agent to demonstrate hard cardiovascular event reduction.
Mechanism of Action
Semaglutide exerts its metabolic, glycaemic, and cardiovascular effects through selective, high-potency agonism at GLP-1 receptors distributed across multiple organ systems:
Pancreatic Beta-Cell Insulin Secretion
GLP-1 receptor activation in pancreatic beta cells potentiates glucose-stimulated insulin secretion through a cAMP/PKA-mediated pathway. This glucose-dependency—the insulinotropic effect is essentially absent at euglycaemia—is the molecular basis for semaglutide's low intrinsic hypoglycaemia risk as monotherapy. Semaglutide's high GLP-1 receptor binding affinity and DPP-4 resistance produce a prolonged, potent stimulation of this pathway, resulting in significant HbA1c reductions.
Pancreatic Alpha-Cell Glucagon Suppression
GLP-1 receptors are expressed on pancreatic alpha cells, where their activation suppresses glucagon secretion in a glucose-dependent manner. Reduced glucagon diminishes hepatic glycogenolysis and gluconeogenesis, lowering fasting and postprandial glucose independently of the direct insulin-secretory effect.
Central Appetite Suppression
This is the dominant mechanism underlying semaglutide's weight-management efficacy. GLP-1 receptors in the hypothalamic arcuate nucleus, paraventricular nucleus, and ventromedial hypothalamus integrate satiety signalling from peripheral nutrient-sensing systems. Semaglutide crosses the blood-brain barrier at circumventricular organs and activates these circuits, reducing hunger, prolonging inter-meal satiety, and attenuating the hedonic drive toward calorie-dense food. Mechanistic studies in human volunteers confirm that ad libitum energy intake is reduced by approximately 35% under semaglutide treatment—the primary driver of weight loss.
Gastric Emptying Delay
Vagal GLP-1 receptor activation slows gastric emptying, moderating the rate of nutrient absorption and blunting postprandial glucose excursions. This effect exhibits tachyphylaxis with chronic treatment; gastric-emptying delay is most prominent in the first 4–8 weeks and partially attenuates during long-term therapy, while appetite suppression and weight loss continue.
Cardiovascular Protective Mechanisms
The SELECT trial data and mechanistic research suggest multiple cardiovascular protective pathways: direct anti-inflammatory effects on vascular endothelium and macrophages via GLP-1 receptor activation; improvements in endothelial function and arterial stiffness; favourable effects on plasma lipids and blood pressure; and indirect benefits mediated through weight reduction and improved glycaemic control. GLP-1 receptors expressed in cardiomyocytes may also confer direct cardioprotective signalling independent of metabolic effects.
Hepatic and Renal Effects
Hepatic GLP-1 receptor activation may reduce hepatic fat accumulation through effects on de novo lipogenesis and fatty acid oxidation, relevant to NASH research. Renal GLP-1 receptor agonism may contribute to natriuresis and blood pressure reduction. The FLOW trial published in 2024 demonstrated that semaglutide significantly reduced progression of chronic kidney disease in type 2 diabetes, adding a nephroprotective dimension to the compound's clinical profile.
Researched Effects
- Mean body-weight reduction of approximately 14.9% at 68 weeks with semaglutide 2.4 mg in STEP 1, involving 1,961 adults with obesity without type 2 diabetes.
- HbA1c reductions of 1.5–1.8 percentage points across SUSTAIN trials in type 2 diabetes populations, with high rates of target attainment at below 7% and below 6.5%.
- 20% relative risk reduction in major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, cardiovascular death) in the SELECT trial in adults with obesity and established cardiovascular disease.
- Significant reductions in C-reactive protein and other inflammatory biomarkers, consistent with a direct anti-inflammatory mechanism beyond metabolic improvement.
- Clinically meaningful reductions in systolic blood pressure (approximately 6 mmHg), triglycerides, and LDL-cholesterol observed across STEP and SUSTAIN programmes.
- Hepatic fat reduction demonstrated in magnetic resonance imaging sub-studies, with exploratory data suggesting histological improvement in NASH.
- Significant reduction in the rate of kidney disease progression in the FLOW trial (2024), establishing a nephroprotective indication in type 2 diabetes.
- Improvements in sleep apnoea severity and physical function scores observed in STEP 5 and long-term extension studies.
Theoretical Research Protocols
- Dosage range
- STEP programme: escalation from 0.25 mg/week to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg over 16–20 weeks; SUSTAIN programme: 0.5 mg and 1.0 mg for diabetes (2.0 mg for Ozempic 2 mg); FLOW renal trial: 1.0 mg weekly
- Frequency
- Once weekly subcutaneous injection; oral semaglutide (Rybelsus) dosed once daily in the fasted state
- Duration
- STEP trials: 68-week primary endpoints; SUSTAIN: 30–104 weeks; SELECT: median 34.2 months follow-up
- Administration routes
- Subcutaneous injection via prefilled pen (Ozempic 0.5–2 mg for diabetes; Wegovy 2.4 mg for weight management) — once weekly, Oral tablet (Rybelsus 3 mg, 7 mg, 14 mg) — once daily, taken 30 minutes before the first meal with minimal water, exploiting absorption at the gastric mucosa
Safety Profile
Common side effects (research)
- Nausea — reported in approximately 20–44% of participants across STEP doses; most common during dose escalation and typically self-limiting
- Diarrhoea — reported in approximately 19–30% of participants in STEP trials
- Vomiting — reported in approximately 5–24% of participants across STEP dose groups
- Constipation — reported in approximately 24% of participants at the 2.4 mg dose in STEP 1
- Headache and fatigue — commonly reported, particularly during dose-escalation phases
- Injection-site reactions including erythema, itching, and transient bruising
- Abdominal pain and dyspepsia reported at low but consistent frequencies across trials
Rare risks
- Acute pancreatitis — a class-level warning; incidence in SELECT and SUSTAIN-6 populations was low (approximately 0.3%) with no statistically significant difference from placebo
- Thyroid C-cell neoplasia — regulatory class warning based on rodent carcinogenicity at supra-pharmacological exposures; no increase in thyroid cancer rates observed in human trial populations
- Diabetic retinopathy progression — observed in SUSTAIN-6 with rapid glycaemic improvement; relevant in participants with pre-existing retinopathy; regular ophthalmological monitoring recommended
- Cholelithiasis — risk elevated with rapid weight loss; gallstone disease was observed at increased rates in STEP trial populations
- Tachycardia — modest resting heart rate increase (approximately 2–5 bpm) consistent with GLP-1 receptor class effects
- Hypoglycaemia — low risk as monotherapy; significantly elevated when combined with insulin or sulphonylureas
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2
- Active or significant history of pancreatitis
- Pregnancy and breastfeeding — weight loss is contraindicated in pregnancy; no clinical data available
- Hypersensitivity to semaglutide or any excipient of the formulation
- Severe gastrointestinal disease including gastroparesis or inflammatory bowel disease with active flare
- Severe renal impairment (eGFR <15 mL/min) — use with caution; dose adjustment guidance varies by formulation
UK Regulatory Status
United Kingdom (MHRA): Semaglutide is an MHRA-licensed prescription-only medicine in the UK in three formulations: Ozempic (0.5 mg, 1 mg, 2 mg subcutaneous) for type 2 diabetes management; Wegovy (2.4 mg subcutaneous) for chronic weight management; and Rybelsus (3 mg, 7 mg, 14 mg oral) for type 2 diabetes. All formulations may only be dispensed by or under the direction of a licensed UK prescriber. Significant supply pressures have led to MHRA supply restriction notifications at various points since 2022. Procurement through unregulated channels is unlawful under the Human Medicines Regulations 2012.
European Union (EMA): Semaglutide holds EMA marketing authorisation for Ozempic (type 2 diabetes) and Wegovy (chronic weight management) and Rybelsus (type 2 diabetes) across EU member states. It is a Schedule-equivalent prescription medicine in all jurisdictions.
Notes: Semaglutide is prohibited by WADA in competitive sport. The clinical evidence base—particularly SELECT's cardiovascular outcomes data—has positioned semaglutide as a landmark compound in cardiometabolic medicine. For research purposes, the rich published literature from STEP, SUSTAIN, SELECT, FLOW, and numerous mechanistic sub-studies makes semaglutide the most thoroughly characterised GLP-1 receptor agonist available.
Related research resources
Key Research Studies
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
A 68-week, randomised, double-blind, placebo-controlled trial enrolling 1,961 adults with obesity (BMI ≥30 kg/m²) or overweight with weight-related comorbidities, without type 2 diabetes. Participants receiving semaglutide 2.4 mg weekly achieved a mean weight reduction of 14.9% versus 2.4% with placebo (difference −12.4 percentage points). Approximately 86% of the semaglutide group achieved ≥5% weight loss versus 32% with placebo, establishing semaglutide as the most efficacious pharmacological weight-management agent at the time of publication.
Read sourceSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
A landmark 4-year, randomised, double-blind, placebo-controlled cardiovascular outcomes trial enrolling 17,604 adults with obesity or overweight (no diabetes) and established cardiovascular disease. Semaglutide 2.4 mg weekly reduced the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 20% (hazard ratio 0.80, 95% CI 0.72–0.90). This was the first demonstration that a pharmacological weight-management intervention reduces hard cardiovascular events in a pre-specified primary outcome.
Read sourceSTEP 2: Semaglutide 2.4 mg in Adults with Overweight or Obesity and Type 2 Diabetes
A 68-week trial in 1,210 adults with overweight/obesity and type 2 diabetes. Semaglutide 2.4 mg produced a mean weight reduction of 9.6% versus 3.4% with placebo, and HbA1c decreased by 1.6 percentage points versus 0.4% with placebo. The attenuated weight-loss relative to STEP 1 is consistent with the diabetes-related counter-regulatory mechanisms that partially resist weight loss.
Read sourceSUSTAIN-6: Cardiovascular and Other Outcomes with Semaglutide in Subjects with Type 2 Diabetes
A 2-year randomised cardiovascular outcomes trial in 3,297 adults with type 2 diabetes and high cardiovascular risk. Semaglutide met the non-inferiority threshold for MACE and demonstrated superiority for the composite primary endpoint (HR 0.74, 95% CI 0.58–0.95), driven primarily by significant reduction in non-fatal stroke. This was the first cardiovascular outcomes trial in type 2 diabetes to report superiority for a GLP-1 receptor agonist.
Read sourceFLOW: Semaglutide and Kidney Outcomes in Type 2 Diabetes
A 3.4-year median follow-up randomised trial in 3,533 adults with type 2 diabetes and chronic kidney disease. Semaglutide 1.0 mg weekly reduced the primary kidney composite endpoint (sustained ≥50% eGFR decline, kidney failure, renal death, or cardiovascular death) by 24% (HR 0.76, 95% CI 0.66–0.88), establishing nephroprotection as a substantiated clinical benefit of GLP-1 receptor agonism.
Read sourceFrequently Asked Questions
What is semaglutide and how does it work?
Semaglutide is a synthetic GLP-1 receptor agonist that mimics the action of the endogenous gut hormone glucagon-like peptide-1. It reduces body weight primarily through central appetite suppression in the hypothalamus, which reduces ad libitum energy intake by approximately 35%. It also delays gastric emptying, stimulates glucose-dependent insulin secretion, and suppresses glucagon. The modifications to its structure—particularly the C-18 fatty diacid chain—extend its half-life to approximately seven days, enabling once-weekly dosing.
Is semaglutide available on the NHS in the UK?
Semaglutide (Ozempic) is available on NHS prescription for type 2 diabetes. Wegovy (semaglutide 2.4 mg) for weight management has been subject to restricted NHS availability and is being phased into NHS specialist weight management services from 2024 onwards under NICE guidance TA875. Rybelsus (oral semaglutide) is also NHS-listed for type 2 diabetes. Availability through private prescribers is more immediate. All forms require a valid prescription.
How does semaglutide compare to tirzepatide for weight loss?
Head-to-head data from SURPASS-2 demonstrate that tirzepatide 15 mg produces greater weight loss (approximately −11.2 kg) than semaglutide 1 mg (approximately −5.7 kg) in type 2 diabetes populations. Indirect comparisons between STEP 1 (semaglutide 2.4 mg, −14.9%) and SURMOUNT-1 (tirzepatide 15 mg, −22.5%) in non-diabetic obesity populations consistently favour tirzepatide, though these comparisons are limited by the absence of a direct head-to-head trial at weight-management doses.
What cardiovascular evidence exists for semaglutide?
The SELECT trial (2023) demonstrated a statistically significant 20% relative reduction in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) in 17,604 adults with obesity and cardiovascular disease but no diabetes over a median 34.2 months. SUSTAIN-6 demonstrated cardiovascular superiority in type 2 diabetes. The FLOW trial (2024) demonstrated 24% reduction in the composite kidney outcomes endpoint. Collectively, these data represent the strongest cardiovascular and end-organ evidence base for any metabolic peptide.
What are the most serious risks associated with semaglutide research?
The most clinically significant risks in trial populations were: gastrointestinal adverse events (nausea, vomiting, diarrhoea, constipation) in 40–50% of participants during dose escalation; gallbladder disease related to rapid weight loss; and diabetic retinopathy complications with rapid glycaemic improvement (particularly in SUSTAIN-6). Acute pancreatitis was reported at low rates without a significant difference from placebo. The thyroid C-cell warning applies across the GLP-1 receptor agonist class.
Is semaglutide being researched for any neurological conditions?
Yes. Semaglutide is under investigation for Parkinson's disease (a Phase 2 trial in the UK reported in 2024 showed slowed motor score deterioration) and Alzheimer's disease, based on preclinical evidence of neuroprotective GLP-1 receptor effects and epidemiological observations of reduced dementia rates in GLP-1 receptor agonist-treated populations. Additionally, the association between semaglutide use and reduced rates of substance use disorder is under mechanistic investigation.
Why was there a semaglutide shortage in the UK?
Demand for Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for weight management) increased substantially from 2022 following publication of STEP trial weight-loss data and associated media coverage. Novo Nordisk's global manufacturing capacity was insufficient to meet this accelerated demand, resulting in MHRA-notified supply disruptions across 2022–2024. Novo Nordisk subsequently invested in significant manufacturing capacity expansion, and supply constraints have progressively improved.
Licensed brand-name medicines
Related trials
Related mechanisms
Related conditions
Type 2 diabetes
Obesity
Prediabetes
Metabolic syndrome
MASLD / MASH (metabolic dysfunction-associated steatotic liver disease)
Obstructive sleep apnoea (OSA)
Heart failure with preserved ejection fraction (HFpEF)
Cardiovascular risk
Chronic kidney disease (CKD)
Visceral adiposity
Sarcopenic obesity and lean-mass concerns
Post-weight-loss maintenance
Weight regain after GLP-1 discontinuation
Polycystic ovary syndrome (PCOS)